Incyte Corporation (NASDAQ: INCY), is in the industry Biotechnology. Based in USA, Incyte Corporation has a market cap of 22875.06. Therefore, Incyte Corporation is a large market cap stock. Today it is currently …
NASDAQ
Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as …
Earnings
... biotech Incyte (INCY) topped Wall Street's Q4 sales expectations early Tuesday, despite a steep slide in profit amid rising costs and Jakafi …
Jakafi sales
Incyte Corporation (the “Company”) entered into a letter ... the “Notes”) for an aggregate of 10,610,782 shares of the Company’s common stock, $.001 par value per share (“Common Stock”). The shares of Common Stock to …
NASDAQ
Incyte Corporation (INCY) traded on unusually high volume on Feb. 24, as the stock gained 7.59% to close at $131.21. On the day, Incyte Corporation saw 9.23 million shares trade hands on 67,583 trades. Considering …
Incyte Corporation
Finally, BMO Capital Markets restated a "buy" rating and issued a $135.00 target price (up previously from $122.00) on shares of Incyte Corporation in a report on Tuesday, January 10th. "Ltd. Raises Stake in Incyte
Corporation
Agenus is having an incredibly strong day in the market today. When the trading session started for the day, the stock was already trading well into the green. From there, the stock dipped a bit before a strong continuation …
Amended Agreement
Incyte (INCY) and their partner Lilly announced that the European ... editor The Medical Technology Stock Letter. This is the first regulatory …